Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia

Cell Cycle

Volumn 10, Issue 7, 2011, Pages 1031-1036

  D'Altri, Teresa ^a   Gonzalez, Jessica ^a   Aifantis, Iannis ^b   Espinosa, Lluis ^a   Bigas, Anna ^a  

^a HOSPITAL DEL MAR   (Spain)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

CYLD; Hes; NF kappaB; Notch; T ALL

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR HES 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSFER; GENE ACTIVITY; GENE REPRESSION; GENE SILENCING; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 79953668273     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.7.15067     Document Type: Article

References (33)

1. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137:216-33.
2. Kageyama R, Ohtsuka T. The Notch-Hes pathway in mammalian neural development [In Process Citation]. Cell Res 1999; 9:179-88. (Pubitemid 129623500)
3. Koch U, Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol 2010; 92:411-55.
4. Pear WS, Aster JC. T cell acute lymphoblastic leukemia/ lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling. Curr Opin Hematol 2004; 11:426-33. (Pubitemid 39491437)
5. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-71. (Pubitemid 39336870)
6. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E, et al. Functional interaction between SEL-10, an F-box protein and the nuclear form of activated Notch1 receptor. J Biol Chem 2001; 276:34371-8.
7. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204:1825-35. (Pubitemid 47236320)
8. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated notch alleles. J Exp Med 1996; 183:2283-91. (Pubitemid 26158919)
9. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13:1203-10. (Pubitemid 47530629)
10. Karin M, Greten FR. NFkappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59. (Pubitemid 41400849)
11. Vallabhapurapu S, Karin M. Regulation and function of NFkappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
12. Chen ZJ. Ubiquitin signalling in the NFkappaB pathway. Nat Cell Biol 2005; 7:758-65.
13. Aifantis I, Vilimas T, Buonamici S. Notches, NFkappaBs and the making of T cell leukemia. Cell Cycle 2007; 6:403-6.
14. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, et al. Targeting the NFkappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13:70-7. (Pubitemid 46067388)
15. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch/Hes1 pathway sustains NFkappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18:268-81.
16. Aguilera C, Hoya-Arias R, Haegeman G, Espinosa L, Bigas A. Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression. Proc Natl Acad Sci USA 2004; 101:16537-42. (Pubitemid 39557748)
17. Wendorff AA, Koch U, Wunderlich FT, Wirth S, Dubey C, Bruning JC, et al. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity 2010; 33:671-84.
18. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009; 353-61.
19. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464:1052-7.
20. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462:182-8.
21. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27:4352-6.
22. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NFkappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-30. (Pubitemid 47199123)
23. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131-44.
24. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712-6.
25. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717-21.
26. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7:411-7.
27. Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR, et al. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NFkappaB activation in drug resistance. Cancer Res 1998; 58:3059-65. (Pubitemid 28335087)
28. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91:4624-31. (Pubitemid 28270311)
29. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NFkappaB by activated glucocorticoid receptors. Mol Cell Biol 1995; 15:943-53.
30. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15:50-8.
31. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP, et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009; 46:166-75.
32. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Downregulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009; 206:221-32.
33. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003; 4:451-61. (Pubitemid 38050042)